Anteris Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Anteris Technologies heeft een totaal eigen vermogen van A$4.7M en een totale schuld van A$248.9K, wat de schuld-eigenvermogensverhouding op 5.3% brengt. De totale activa en totale passiva bedragen respectievelijk A$26.5M en A$21.8M.

Belangrijke informatie

5.3%

Verhouding schuld/eigen vermogen

AU$248.93k

Schuld

Rente dekkingsratio	n/a
Contant	AU$10.84m
Aandelen	AU$4.71m
Totaal verplichtingen	AU$21.82m
Totaal activa	AU$26.53m

Recente financiële gezondheidsupdates

Recent updates

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$16.9M ) van AVR } dekken niet de korte termijn passiva ( A$17.7M ).

Langlopende schulden: De kortetermijnactiva AVR ( A$16.9M ) overtreffen de langetermijnschulden ( A$4.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: AVR heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van AVR is de afgelopen 5 jaar gedaald van 9.9% naar 5.3%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: AVR heeft voldoende cash runway voor 2 maanden op basis van de laatst gerapporteerde vrije kasstroom, maar heeft sindsdien extra kapitaal opgehaald.

Voorspelling contante baan: Er wordt voorspeld dat AVR voldoende kasmiddelen zal hebben voor 1 maanden op basis van de vrije kasstroom schattingen, maar heeft sindsdien extra kapitaal opgehaald.

Anteris Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

Recent updates

Consensus revenue estimates increase by 12%, EPS downgraded

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023)

Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million.

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven